Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study

Lancet Oncology

Volumn 8, Issue 2, 2007, Pages 111-118

  Ng, Quan Sing ^a   Goh, Vicky ^b   Milner, Jessica ^a   Stratford, Michael R ^b   Folkes, Lisa K ^b   Tozer, Gillian M ^c   Saunders, Michele I ^a   Hoskin, Peter J ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IOBITRIDOL; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; XENETIX 300;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; FEMALE; HEART PALPITATION; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; SINUS BRADYCARDIA; STUDENT T TEST; SYNTHESIS; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

ADULT; AGED; BLOOD PRESSURE; BLOOD VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HEART RATE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 33846546058     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70001-3     Document Type: Article

References (46)

1. Alderton W., Cooper C., and Knowles R. Nitric oxide synthases: structure, function and inhibition. Biochem J 357 (2001) 593-615
2. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101 (1998) 2567-2578
3. Papapetropoulos A., Garcia-Cardena G., Madri J., et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100 (1997) 3131-3139
4. Gratton J., Lin M., Yu J., et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4 (2003) 31-39
5. Hofseth L., Hussain S., Wogan G., et al. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 34 (2003) 955-968
6. Crowell J., Steele V., Sigman C., et al. Is inducible nitric oxide synthase a target for chemoprevention?. Mol Cancer Ther 2 (2003) 815-823
7. Thomsen L., Lawton F., Knowles R., et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54 (1994) 1352-1354
8. Cobbs C., Brenman J., Aldape K., et al. Expression of nitric oxide synthase in human central nervous system tumours. Cancer Res 55 (1995) 727-730
9. Vakkala M., Kahlos K., Lakari E., et al. Inducible nitric oxide synthase expression, apoptosis and angiogenesis in situ and invasive breast carcinomas. Clin Cancer Res 6 (2000) 2408-2415
10. Klotz T., Bloch W., Volberg C., et al. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 2 (1998) 1897-1903
11. Fujimoto H., Ando Y., Yamashita T., et al. Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res 88 (1997) 1190-1198
12. Gallo O., Masini E., Morbidelli L., et al. Role of nitric oxide in angiogenesis and tumour progression in head and neck cancer. J Natl Cancer Inst 90 (1998) 587-596
13. Fukumura D., Kashiwagi S., and Jain R. The role of nitric oxide in tumour progression. Nat Rev Cancer 6 (2006) 521-534
14. Lala P., and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2 (2001) 149-156
15. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99 (1997) 2625-2634
16. Veikkola T., Karkkainen M., Claesson-Welsh L., et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60 (2000) 203-212
17. Fukumura D., Gohongi T., Kadambi A., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98 (2001) 2604-2609
18. Tozer G., Prise V., and Chaplin D. Inhibition of nitric oxide synthase induces a selective reduction in tumour blood flow that is reversible with L-arginine. Cancer Res 57 (1997) 948-955
19. Haynes W., Noon J., Walker B., et al. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 11 (1993) 1375-1380
20. Lorente J., Landin L., De Pablo R., et al. L-arginine pathway in the sepsis syndrome. Crit Care Med 21 (1993) 1287-1295
21. Yi C., Lee K., Kim E., et al. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233 (2004) 191-199
22. Tateishi U., Nishihara H., Tsukamoto E., et al. Lung tumours evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 26 (2002) 185-190
23. Jinzaki M., Tanimoto A., Mukai M., et al. Double phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumour angiogenesis. J Comput Assist Tomogr 24 (2000) 835-842
24. Ng Q., Goh V., Fichte H., et al. Lung cancer perfusion using MDCT: reproducibility of whole tumour quantitative measurements. Radiology 239 (2006) 547-553
25. Ng Q., Goh V., Klotz E., et al. Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumour volume coverage?. Am J Roentgenol 187 (2006) 1079-1084
26. Pollard R., Garcia T., Stieger S., et al. Quantitative evaluation of perfusion and permeability of peripheral tumours using contrast-enhanced computed tomography. Invest Radiol 39 (2004) 340-349
27. Ford J., Miles K., Hayball M., et al. A simplified method for measurement of blood-brain barrier permeability using CT: preliminary results and the effect of RMP-7. In: Faulkner K., Carey B., Crellin A., and Harrison R. (Eds). Quantitative imaging in oncology (1996), British Institute of Radiology, London 1-5
28. Dugdale P., Miles K., Kelley B., et al. CT measurements of perfusion and permeability within lymphoma masses: relationship to grade, activity and chemotherapeutic response. J Comput Tomogr 23 (1999) 540-547
29. Harvey C., Dooher A., Morgan J., et al. Imaging of tumour therapy responses by dynamic CT. Eur J Radiol 30 (1999) 221-226
30. Kostourou V., Robinson S., Whitley G., et al. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumour angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 63 (2003) 4960-4966
31. Tabrizi-Fard M., and Fung H. Reversed-phase high-performance liquid chromatography method for the analysis of nitro-arginine in rat plasma and urine. J Chromatogr B Biomed Appl 679 (1996) 7-12
32. Miles K. Perfusion CT for the assessment of tumour vascularity: which protocol?. Br J Radiol 76 (2003) S36-S42
33. Crone C. The permeability of capillaries in various organs as determined by use of the 'indicator diffusion' method. Acta Physiol Scand 58 (1963) 292-305
34. Renkin E. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscle. Am J Physiol 197 (1959) 1205-1210
35. Orucevic A., and Lala P. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br J Cancer 73 (1996) 189-196
36. Camp E., Yang A., Liu W., et al. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res 12 (2006) 2628-2633
37. Kubes P., Suzuki M., and Granger D. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88 (1991) 4651-4655
38. Moncada S., Palmer R., and Higgs E. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
39. Jenkins D., Charles I., Thomsen L., et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92 (1995) 4392-4396
40. Fukumura D., Yuan F., Endo M., et al. Role of nitric oxide in tumour microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 150 (1997) 713-725
41. Willett C., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
42. Kiessling F., Boese J., Corvinus C., et al. Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring?. Eur Radiol 14 (2004) 1226-1233
43. Gandhi D., Chepeha D., Miller T., et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol 27 (2006) 101-106
44. Goh V., Halligan S., Hugill J., et al. Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. AJR Am J Roentgenol 187 (2006) 164-169
45. Peterson H. Modification of tumour blood flow--a review. Int J Radiat Biol 60 (1991) 201-210
46. Boucher Y., Baxter L., and Jain R. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50 (1990) 4478-4484